Haemonetics Corporation

Company Profile

Haemonetics Corporation had its IPO on 1991-05-09 under the ticker symbol HAE.

The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Haemonetics Corporation has a staff strength of 3,034 employees.

Stock update

Shares of Haemonetics Corporation opened at $90.65 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $89.7 - $91.88, and closed at $89.96.

This is a -0.87% slip from the previous day's closing price.

A total volume of 280,728 shares were traded at the close of the day’s session.

In the last one week, shares of Haemonetics Corporation have slipped by -0.31%.

Haemonetics Corporation's Key Ratios

Haemonetics Corporation has a market cap of $4.60 billion, indicating a price to book ratio of 5.6502 and a price to sales ratio of 3.6098.

In the last 12-months Haemonetics Corporation’s revenue was $1.22 billion with a gross profit of $530.77 million and an EBITDA of $284.23 million. The EBITDA ratio measures Haemonetics Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Haemonetics Corporation’s operating margin was 15.6% while its return on assets stood at 6.28% with a return of equity of 16.71%.

In Q2, Haemonetics Corporation’s quarterly earnings growth was a positive 110.5% while revenue growth was a positive 19.1%.

Haemonetics Corporation’s PE and PEG Ratio

Forward PE

25.4453

Trailing PE

33.8619

PEG

2.1515

Its diluted EPS in the last 12-months stands at $2.68 per share while it has a forward price to earnings multiple of 25.4453 and a PEG multiple of 2.1515. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Haemonetics Corporation’s profitability.

Haemonetics Corporation stock is trading at a EV to sales ratio of 4.3328 and a EV to EBITDA ratio of 20.6478. Its price to sales ratio in the trailing 12-months stood at 3.6098.

Haemonetics Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.96 billion

Total Liabilities

$236.94 million

Operating Cash Flow

$-15261000.00

Capital Expenditure

$9.66 million

Dividend Payout Ratio

0%

Haemonetics Corporation ended 2024 with $1.96 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.96 billion while shareholder equity stood at $864.62 million.

Haemonetics Corporation ended 2024 with $37.34 million in deferred long-term liabilities, $236.94 million in other current liabilities, 507000.00 in common stock, $284.02 million in retained earnings and $465.91 million in goodwill. Its cash balance stood at $285.72 million and cash and short-term investments were $285.72 million. The company’s total short-term debt was $13,572,000 while long-term debt stood at $751.38 million.

Haemonetics Corporation’s total current assets stands at $801.61 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $177.12 million compared to accounts payable of $78.13 million and inventory worth $289.21 million.

In 2024, Haemonetics Corporation's operating cash flow was $-15261000.00 while its capital expenditure stood at $9.66 million.

Comparatively, Haemonetics Corporation paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$89.96

52-Week High

$95.26

52-Week Low

$71.63

Analyst Target Price

$105.29

Haemonetics Corporation stock is currently trading at $89.96 per share. It touched a 52-week high of $95.26 and a 52-week low of $95.26. Analysts tracking the stock have a 12-month average target price of $105.29.

Its 50-day moving average was $89.04 and 200-day moving average was $84.15 The short ratio stood at 4.19 indicating a short percent outstanding of 0%.

Around 83.6% of the company’s stock are held by insiders while 10132.3% are held by institutions.